- Companies
- Perspectum
Perspectum Funding, Investors & Competitors
Perspectum has raised $119M across 7 funding rounds, most recently a $19M Series C in March 2023.
Last Perspectum funding round
$19M
Series C · Mar 2023
Cumulative funding Perspectum raised
$119M
across 7 funding rounds
Key investors in Perspectum
The Blue Venture Fund
HealthQuest Capital
Oppenheimer Holdings
Puhua Capital
Oxford Science Enterprises
EASME
British Patient Capital
University of Oxford
About Perspectum
Perspectum is a UK-based medical imaging and diagnostics company that originated as a University of Oxford spin-out, developing non-invasive software that converts MRI scan data into quantitative clinical insights for chronic metabolic diseases, multi-organ pathologies, and cancer. Its flagship product, LiverMultiScan, is FDA-approved software that extracts data from standard MRI scans to assess liver tissue and improve diagnosis of conditions such as non-alcoholic fatty liver disease and steatohepatitis. The company also operates a contract research organization that supports biopharmaceutical firms developing liver and metabolic disease treatments, delivering its software-as-a-service platform to roughly 350 locations worldwide.
Founded
2012
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Licensing, Subscription
Perspectum Funding History
Perspectum has raised a total of $119M across 7 funding rounds.
Perspectum's first fundraising round was a $900K seed round in October 2013. The most recent completed round was a $19M Series C in March 2023.
Perspectum funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Mar 2023 | Series C | Oppenheimer Holdings (lead) | $19M | - |
| Jan 2023 | Series C | Oppenheimer Holdings (lead); HealthQuest Capital; The Blue Venture Fund; British Patient Capital | $38M | Perspectum is a UK-based medical imaging and diagnostic technology company specializing in non-invasive solutions for chronic metabolic diseases, multi-organ pathologies, and cancer, delivering software-as-a-service (SaaS) platform products via the Perspectum Portal to approximately 350 global locations. The company raised $55 million in a Series C funding round announced on March 16, 2023, led by Oppenheimer & Co., which invested $27 million through its Private Market Opportunities initiative, with participation from British Patient Capital, HealthQuest Capital, and The Blue Venture Fund. This round supports Perspectum's growth in precision medicine and innovative diagnostics in the healthcare sector. Perspectum's technologies aim to address a total addressable market exceeding $30 billion in the US by converting imaging data into actionable clinical insights without on-site software deployment. |
| Apr 2020 | Series B | HealthQuest Capital (lead); The Blue Venture Fund (lead); Puhua Capital; University of Oxford; Oxford Science Enterprises | $36M | Perspectum is a UK-based medical software company originating as a University of Oxford spin-out, specializing in non-invasive imaging technology for detecting and monitoring diseases, particularly chronic liver disease. Its flagship product, LiverMultiScan, is an FDA-approved software that extracts quantitative data from standard MRI scans to assess liver tissue, improving diagnostics for conditions like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The company also operates an imaging-focused Contract Research Organization (CRO) supporting biopharmaceutical firms in liver and metabolic disease development. On April 14, 2020, Perspectum closed a $36 million Series C financing round co-led by HealthQuest Capital and The Blue Venture Fund, with participation from Oxford Science Innovation (also referred to as Oxford Science Enterprises), Puhua Capital, the University of Oxford, and other existing investors. This brought total funding at the time toward cumulative raises later reported as over $96 million across multiple rounds. Proceeds from the round were allocated to commercialize LiverMultiScan for clinical use, expand the CRO business, and develop new products targeting biliary disease, diabetes, and cancer for both clinical and research applications. HealthQuest Capital, a Bay Area growth capital firm managing over $850 million, brings expertise in diagnostics and clinical trial services, while The Blue Venture Fund offers insights into reimbursement and coverage. Perspectum's technology positions it to advance pharmaceutical development, enhance clinical care, and lead in imaging biomarkers for hepatic disease, as noted by investors. Founder and CEO Dr. Rajarshi Banerjee highlighted the strategic value of the lead investors' experience in scaling healthcare companies. |
| Jan 2017 | Undisclosed stage | - | $16M | - |
| Jan 2016 | Seed | EASME (lead) | $5M | - |
| Nov 2015 | Seed | - | $5M | - |
| Oct 2013 | Seed | Oxford University Innovation (lead) | $900K | - |
Who has invested in Perspectum?
9 investors have backed Perspectum across its funding rounds, including The Blue Venture Fund, HealthQuest Capital, Oppenheimer Holdings, Puhua Capital, Oxford Science Enterprises and EASME.
Lead investors include Oppenheimer Holdings, HealthQuest Capital, The Blue Venture Fund, EASME and Oxford University Innovation.
Perspectum Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Apr 2020 | ||
| 2 | Lead | Apr 2020 | ||
| 2 | Lead | Jan 2023 | ||
| 1 | Participant | Apr 2020 | ||
| 1 | Participant | Apr 2020 | ||
| 1 | Lead | Oct 2013 | ||
| 1 | Participant | Apr 2020 | ||
This data is available for Pro users. Sign up to see all 9 Perspectum investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialPerspectum Competitors
Perspectum competitors include listed companies like GE HealthCare, United Imaging, Pro Medicus and RaySearch Labs, and private ones like United Imaging Intelligence and Viz.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x | ||
| Private | - | - | $1.4B | - | ||
| Publicly listed | $186M | $147M | $13B | 62.7x | ||
| Private | $100M | - | $1.3B | 12.8x | ||
| Publicly listed | $137M | $59M | $583M | 4.2x |
Perspectum Public Comps
Perspectum is still privately-owned, but its public comps include Natera, IQVIA, Agilent, Veeva, IDEXX Laboratories, Roper Technologies, GE HealthCare, Quest Diagnostics, Labcorp and Guardant Health.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $2.3B | ($266M) | 22.5x | 19.0x | (195.0x) | (261.5x) | |||
| $16B | $3.4B | 3.6x | 3.4x | 17.2x | 14.8x | |||
| $6.9B | $1.8B | 6.7x | 6.2x | 26.1x | 21.0x | |||
| $3.2B | $965M | 11.1x | 10.2x | 36.9x | 22.4x | |||
| $4.3B | $1.5B | 9.5x | 8.9x | 27.1x | 24.9x | |||
| $7.9B | $3.2B | 6.1x | 5.7x | 15.2x | 14.6x | |||
| $21B | $3.7B | 1.8x | 1.8x | 10.1x | 10.0x | |||
| $11B | $2.2B | 3.0x | 2.9x | 15.5x | 14.5x | |||
This data is available for Pro users. Sign up to see all Perspectum competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Perspectum
| When was Perspectum founded? | Perspectum was founded in 2012. |
| Where is Perspectum headquartered? | Perspectum is headquartered in United Kingdom. |
| Is Perspectum publicly listed? | No, Perspectum is a private, VC-backed company. |
| How much funding has Perspectum raised? | Perspectum has raised $119M across 7 funding rounds. |
| What was Perspectum's last funding round? | Perspectum's last funding round was a $19M Series C in March 2023, led by Oppenheimer Holdings. |
| Who are Perspectum's investors? | Perspectum's investors include HealthQuest Capital, The Blue Venture Fund, Oppenheimer Holdings, Puhua Capital, University of Oxford, Oxford University Innovation, Oxford Science Enterprises, British Patient Capital and EASME. |
| Which companies are comparable to Perspectum? | Companies comparable to Perspectum include GE HealthCare, United Imaging, United Imaging Intelligence, Pro Medicus, Viz and RaySearch Labs. |
See companies similar to Perspectum
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




